Levamisole (Decaris)

Subscribe to Selected New Research on Levamisole

1694 relevant articles (208 outcomes, 287 trials/studies) found for this Drug

Description: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)

Also Known As:

Decaris; Dekaris; Levamisole Hydrochloride; Solaskil; Hydrochloride, Levamisole; L-Tetramisole; Levotetramisole; Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)-

Relationship Network

Drug Context: Research Results

Experts

1.	Wang, Bin: 2 articles (03/2008 - 01/2007)
2.	Jin, Huali: 2 articles (03/2008 - 01/2007)
3.	Chiang, C P: 2 articles (05/2007 - 10/2001)
4.	Sun, A: 2 articles (05/2007 - 10/2001)
5.	Macdonald, John S: 2 articles (12/2005 - 03/2005)
6.	Haller, Daniel G: 2 articles (12/2005 - 03/2005)
7.	Mayer, Robert J: 2 articles (12/2005 - 03/2005)
8.	Staib, Ludger: 2 articles (08/2005 - 01/2003)
9.	Behzadi, Ashkan Heshmatzade: 1 article (08/2008)
10.	Ansarin, Habib: 1 article (08/2008)

Related Diseases

1.	Infection 01/01/1982 - "Levamisole was most effective for treating rats seven days after infection but its efficacy dropped as infection progressed. " 07/01/1983 - "Aggressive antiviral therapy (e.g., with IF) followed by immunostimulation (e.g., with Levamisole) may prove effective in controlling certain viral infections in immunodeficiency disorders." 07/10/1982 - "A trial involving 122 calves of approximately 100 kg bodyweight was undertaken to assess the protection against reinfection with Dictyocaulus viviparus in calves whose primary infection was treated with levamisole. " 03/01/2000 - "Levamisole, a non-specific immunopotentiator gave protection against infection induced by A. " 06/01/1998 - "The results show an increase in the cell-mediated immunity response in the levamisole-treated group, thereby suggesting that levamisole may help to speed the recovery of malnourished children suffering from various infections." Order ALL the reference details at left...
2.	Colonic Neoplasms (Colon Cancer) 03/20/2005 - "Intergroup trial 0153 (Southwest Oncology Group trial 9415) was developed to compare the efficacy of continuous-infusion FU (CIFU) plus levamisole to FU/LV plus levamisole in the adjuvant treatment of high-risk Dukes' B2 and C1 or C2 colon cancer. " 11/15/1994 - "The importance of interactions between immune cells and neoplastic cells in influencing the pathogenesis of colon cancer is suggested by the clinical efficacy of levamisole, an immunostimulant, in the treatment of colon cancer and by the association of local lymphocytic infiltration with improved prognosis. " 01/01/2001 - "Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints." 01/01/2006 - "BACKGROUND: Levamisole (LMS) has immunomodulatory activity, stimulates the immune system of healthy, normal volunteers and has been proposed previously as a colon cancer preventive agent. " 04/01/2004 - "MATERIALS AND METHODS: Colon 205 cells, a human colonic cancer cell line, were exposed to Escherichia coli LPS (1 microg/mL) in the presence of levamisole (1 microm to 1 mm). " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 01/01/1977 - "In different forms of cancer, when most of the tumor volume is first reduced, levamisole therapy significantly increases both remission and survival. " 02/01/1979 - "The results suggest that levamisole is effective in the patients whose tumor cells have been decreased by any method." 11/01/1978 - "These results demonstrate the efficacy of levamisole as a restorative agent of the general and tumor-associated immunocompetency in the immunodepressed host." 11/01/1991 - "Numerous preclinical evaluations and clinical trials with levamisole in the cancer arena have been sponsored by the National Cancer Institute and other agencies worldwide with the hopes of demonstrating anticancer activity. " 05/01/1987 - "Results are reported of a double-blind randomized study on 198 patients with resectable node positive mammary cancer, evaluating the effect of the immune modulating drug levamisole in an adjuvant setting. " Order ALL the reference details at left...
4.	Rheumatoid Arthritis 01/01/1982 - "This cytotoxic defect may be an important pathogenetic factor in rheumatoid arthritis and this new assay may be helpful in selecting candidates who are most likely to respond to levamisole." 10/08/1978 - "The comparison of blood eosinophil counts and stool parasites in two groups of patients--twenty one suffering from rheumatoid arthritis and twenty one from other various diseases--did not show any significant difference in favour of a parasitological etiology in rheumatoid arthritis, an hypothesis which had to be considered because of the efficacy of levamisole in the treatment of this disease." 11/01/1981 - "A randomized, double-blind study was performed to compare the efficacy of 2 different regimens for levamisole in the treatment of rheumatoid arthritis over a period of six months. " 04/01/1979 - "Treatment with levamisole frequently results in clinical improvement in rheumatoid arthritis, but this is not clearly related to a stimulatory effect on cell-mediated immunity. " 09/04/1976 - "A case of classical rheumatoid arthritis of 12 years' duration, was treated during an exacerbation with levamisole and remission was induced. " Order ALL the reference details at left...
5.	Nephrotic Syndrome (Syndrome, Nephrotic) 02/01/2006 - "Thus, we concluded that levamisole is a highly efficacious, safe and easily affordable initial therapy for FR/SD idiopathic nephrotic syndrome." 01/01/1994 - "The clinically significant trend towards increased duration of remission maintenance in steroid-sensitive nephrotic syndrome observed with levamisole therapy, especially in patients with multiple relapses, may require a larger study with a longer follow-up for definitive confirmation." 01/01/2006 - "CONCLUSION: Levamisole is a safe and effective steroid sparing drug, in steroid dependent and frequently relapsing nephrotic syndrome, for the prolongation of remission, especially in older children." 04/01/2008 - "Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome." 09/01/2002 - "OBJECTIVE: To evaluate the effectiveness of levamisole in maintaining remission in children with steroid-sensitive nephrotic syndrome (SSNS) who had a frequent relapsing or steroid-dependent course. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Leucovorin (Folinic Acid)
3.	Mebendazole (Vermin)
4.	Interferons
5.	Ivermectin (Mectizan)
6.	Doxorubicin (Adriamycin)
7.	Levamisole (Decaris)
8.	Immunologic Factors (Immunomodulators)
9.	Prednisolone (Predate)
10.	Pyrantel Pamoate (Pyrantel Embonate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Adjuvant Chemotherapy
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Injections

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>